DR. MEHER BURKI M.D.
Prescription History 1184877813
Internal Medicine - Hematology & Oncology in West Chester, PA


Quality Rating: 85.48 out of 100 score

NPI Status: Active since October 26, 2008

Contact Information

440 E MARSHALL ST
SUITE 201
WEST CHESTER, PA
ZIP 19380
Phone: (610) 738-2500

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. MEHER BURKI M.D., an active Hematology & Oncology specialist practicing in West Chester, PA. Our medical registry currently tracks 14 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 751 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 298 claims alone.


Alendronate Sodium

Generic Formulation: Alendronate SodiumSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 75
30-Day Fills 116.3
Days Supply 3,389
PA State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills90.4
Peer Average Days Supply2,652
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 70.5% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $481.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.42

State Avg Cost Per Claim

$11.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Therapeutic Applications

Alendronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss. This effect helps maintain strong bones and reduce the risk of broken bones (fractures). Alendronate belongs to a class of drugs called bisphosphonates.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 298
30-Day Fills 780.6
Days Supply 23,355
PA State Average Benchmarks
Peer Average Claims69.0
Peer Average 30-Day Fills155.9
Peer Average Days Supply4,637
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 331.9% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,049.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$30.37

State Avg Cost Per Claim

$27.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Eliquis

Generic Formulation: ApixabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 43
30-Day Fills 82.0
Days Supply 2,458
PA State Average Benchmarks
Peer Average Claims92.0
Peer Average 30-Day Fills137.0
Peer Average Days Supply3,769
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.3% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $47,631.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,107.72

State Avg Cost Per Claim

$730.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Gabapentin

Generic Formulation: GabapentinSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 27
30-Day Fills 55.0
Days Supply 1,650
PA State Average Benchmarks
Peer Average Claims97.0
Peer Average 30-Day Fills141.8
Peer Average Days Supply4,057
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.2% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $259.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.61

State Avg Cost Per Claim

$21.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 27
30-Day Fills 46.6
Days Supply 1,388
PA State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills60.0
Peer Average Days Supply1,765
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $992.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$36.78

State Avg Cost Per Claim

$33.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
PA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.6
Peer Average Days Supply672
Conservative Utilization

This provider writes prescriptions for this formulation 40.9% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,961.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$150.92

State Avg Cost Per Claim

$2,955.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Letrozole

Generic Formulation: LetrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 49
30-Day Fills 142.3
Days Supply 4,270
PA State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills100.1
Peer Average Days Supply2,980
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,241.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$45.75

State Avg Cost Per Claim

$26.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 61
30-Day Fills 63.0
Days Supply 869
PA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.8
Peer Average Days Supply309
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 134.6% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $395.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.48

State Avg Cost Per Claim

$15.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Oxycodone Hcl

Generic Formulation: Oxycodone HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.7
Days Supply 246
PA State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills54.4
Peer Average Days Supply1,033
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 66.7% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $221.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.30

State Avg Cost Per Claim

$22.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic derivative of CODEINE.

Therapeutic Applications

This medication is used to help relieve moderate to severe pain. Oxycodone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Prochlorperazine Maleate

Generic Formulation: Prochlorperazine MaleateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 40
30-Day Fills 40.0
Days Supply 357
PA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills29.9
Peer Average Days Supply412
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 37.9% more claims than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $419.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.50

State Avg Cost Per Claim

$18.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Therapeutic Applications

This medication is used to treat severe nausea and vomiting from certain causes (for example, after surgery or cancer treatment). Prochlorperazine belongs to a class of drugs known as phenothiazines. This medication is not recommended for use in children younger than 2 years or in children going through surgery.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 37
30-Day Fills 85.0
Days Supply 2,546
PA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills69.5
Peer Average Days Supply2,063
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $819.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.15

State Avg Cost Per Claim

$32.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Tramadol Hcl

Generic Formulation: Tramadol HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 158
PA State Average Benchmarks
Peer Average Claims52.0
Peer Average 30-Day Fills54.3
Peer Average Days Supply1,092
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 76.9% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $100.39 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.37

State Avg Cost Per Claim

$7.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A narcotic analgesic proposed for severe pain. It may be habituating.

Therapeutic Applications

See also Warning section. This medication is used to help relieve moderate to moderately severe pain. Tramadol belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Warfarin Sodium

Generic Formulation: Warfarin SodiumSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 20
30-Day Fills 24.0
Days Supply 720
PA State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills98.1
Peer Average Days Supply2,595
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.3% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $165.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.30

State Avg Cost Per Claim

$12.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.

Therapeutic Applications

This medication is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and/or to prevent new clots from forming in your body. Preventing harmful blood clots helps to reduce the risk of a stroke or heart attack. Conditions that increase your risk of developing blood clots include a certain type of irregular heart rhythm (atrial fibrillation), heart valve replacement, recent heart attack, and certain surgeries (such as hip/knee replacement). Warfarin is commonly called a blood thinner, but the more correct term is anticoagulant. It helps to keep blood flowing smoothly in your body by decreasing the amount of certain substances (clotting proteins) in your blood.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 31
30-Day Fills 71.4
Days Supply 2,142
PA State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills78.6
Peer Average Days Supply2,206
Conservative Utilization

This provider writes prescriptions for this formulation 35.4% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $39,471.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,273.26

State Avg Cost Per Claim

$800.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. MEHER BURKI M.D. provides transparency into local medical care patterns within West Chester, PA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.